# BPC-157: A Gastric Name and an Injected Evidence Base > BPC-157: A Gastric Name and an Injected Record — Research Peptide Fundamentals — BPC-157 in the Research Peptide Fundamentals series: what the rodent literature shows, why the human record is three pilot studies, and why the only measured route for this research peptide is a needle. **01 / ABSORPTION** Named for the gastric juice its parent protein came from, sold in capsules on the strength of that name, and measured in humans only through a needle. ## The short version BPC-157 is a synthetic chain of fifteen amino acids copied from part of a protein found in human gastric juice. Nearly everything known about it comes from rats. In those animals it speeds the healing of injured tendon, muscle and gut tissue, and the best-supported explanation is that it helps build new blood vessels into damaged tissue. The human record is thin enough to state in one sentence. A 2025 review counted three small pilot studies and no rigorous large trial [2]. It is not an approved medicine anywhere, it is sold for laboratory research use only, and it is banned in competitive sport at all times. Its gastric name is the reason it turns up in capsules and sprays. That name refers to where the parent protein was found, not to any demonstrated ability to survive digestion. The only formal human pharmacokinetic work used an injected route [3], and the foundational ulcer study that built its reputation found injection outperforming delivery into the stomach [5]. ## What it is BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide: fifteen amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val [5]. It is derived from a partial sequence of BPC, a protein identified in human gastric juice, and it also appears under several research designations. Its category is usually given as a stable gastric pentadecapeptide, and that is where a good deal of confusion starts. The descriptor points at the environment the parent protein was found in. It is not a measurement of how much of a swallowed dose reaches the blood, and no study cited on this site reports such a measurement. Its regulatory position is unambiguous. It is not approved for human use in any jurisdiction. The United States Food and Drug Administration has placed it in a category of bulk drug substances identified as not eligible for pharmacy compounding, pending further evaluation. The World Anti-Doping Agency prohibits it in sport at all times under the non-approved-substances category. Research suppliers list it for laboratory use only, and not for human consumption. ## How it works The mechanism reported most consistently is angiogenesis, the growth of new blood vessels into tissue that needs repair. In cell and animal work BPC-157 up-regulates the VEGFR2 receptor and promotes its internalisation, with downstream signalling through the VEGFR2-Akt-eNOS pathway and the nitric-oxide system [4]. Several secondary routes appear alongside it. The peptide has been described as acting on the FAK-paxillin complex, which governs cell migration, and as sensitising the growth-hormone receptor in tendon fibroblasts. A separate line of work positions it as a mediator on the brain-gut axis that modulates serotonergic and dopaminergic systems and engages the Egr-1, NAB2, FAK-paxillin and JAK-2 pathways [7]. None of that mechanism has anything to say about absorption. A molecule can have a well-characterised receptor interaction and still be destroyed long before it reaches one, and the two questions get answered by entirely different experiments. Mechanism papers describe what happens once a peptide is in contact with tissue. They are not evidence about how it got there. ## What the research shows The animal literature is broad and internally consistent. In a foundational gastric-ulcer model, BPC 157 reduced ulcer area and accelerated healing, and that same study compared routes: intramuscular delivery outperformed intragastric [5]. In a fully transected rat Achilles tendon, it accelerated healing across biomechanical, functional, microscopic and macroscopic measures and stimulated tendocyte outgrowth in culture [6]. The pharmacokinetic picture arrived much later. The first formal characterisation of absorption, distribution, metabolism and excretion found linear pharmacokinetics, a very short elimination half-life, modest bioavailability by an intramuscular route, and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [3]. That intramuscular figure is the only bioavailability measurement for this compound anywhere in this digest's sources. Human data are close to absent. A first-in-human safety pilot infused BPC-157 intravenously at up to 20 mg in two healthy adults and reported no observed adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two healthy adults is a safety signal of the weakest available kind, and the study was not built to measure benefit. A 2025 narrative review states the position plainly: despite broad preclinical support, human data are extremely limited, only three pilot studies exist, rigorous large-scale trials are lacking, and the compound belongs in the investigational category given regulatory controversy and non-regulated availability [2]. The same review notes that a large share of the foundational literature comes from a single research group and its collaborators, which is a real limit on independent replication. ## Reported effects, cautions and safety What follows in this paragraph is anecdotal, not clinical evidence. It summarises what people in research-use communities describe, and no controlled human trial has tested any of it. The most common reason given for trying BPC-157 is stubborn tendon, ligament and joint trouble, and users very commonly report old sprains, tennis elbow and rotator-cuff strains feeling more usable within the first one to three weeks. Reduced joint stiffness and easier movement come up frequently, as do improvements in digestive symptoms such as bloating, cramping and urgency, which people tie to the peptide's gastric origin. A smaller group reports faster closure of minor skin wounds, better sleep or steadier mood, and a general sense of reduced inflammation that is very hard to separate from placebo. On the adverse side, local reactions at the injection site, meaning brief stinging, redness or a small bump that fades within a day, are the single most common complaint. Nausea, loose stools and stomach cramping are reported frequently, and notably more often with oral and sublingual products than with injections. Fatigue in the first week, headache, brief dizziness after a dose and transient flushing appear occasionally. Palpitations are reported rarely, and commentators treat a persistent racing heartbeat, chest pain or a marked blood-pressure change as a reason to stop and seek medical evaluation. The documented cautions are a different category of statement, and they are the part of this page with citations behind it. - The human evidence is extremely thin. Almost everything known comes from rodents, only a handful of small uncontrolled human reports exist, and the real balance of benefit and risk in people is genuinely unknown [1][2]. - Much of the foundational research comes from one group and its collaborators, so a consistent-looking body of findings has not been widely confirmed by unrelated laboratories [2]. - It is not an approved drug, and because it moves through non-regulated channels the identity, purity and actual content of any given product go unverified outside formal studies [2]. - Strong pro-angiogenic activity raises a theoretical concern in cancer. Tumours also depend on new blood vessels, so a strongly pro-angiogenic agent is a mechanism-based worry in anyone with active or suspected disease [4]. - Rodent work shows changes in brain serotonin activity, which raises a theoretical interaction concern with serotonin-raising medicines such as certain antidepressants. No human interaction study exists to settle it. - It promotes growth signalling, and there are no long-term human safety data to say what that means over years. - It is prohibited in sport at all times, which matters for anyone subject to testing. - It has never been tested for safety in pregnancy, in breastfeeding or in children. The last four carry no bracket because the sources behind them sit outside the reference list assembled for this site. They are recorded as cautions, not as findings. ## Where it fits in the oral question On the question this site is organised around, BPC-157 is the clearest case of a gap being filled by a name. The evidence for the injected route is not strong, but it exists: an intramuscular bioavailability figure [3], a route comparison favouring intramuscular over intragastric in the ulcer model [5], and an intravenous safety pilot in two people [1]. The evidence for a swallowed route is not weak. It is absent. No source gathered here reports a human oral or sublingual pharmacokinetic study of BPC-157, and the community reports that mention those formats describe more gastrointestinal upset rather than more effect, which is anecdotal, not clinical evidence and says nothing about whether anything was absorbed. That absence is worth stating precisely, because two different claims get collapsed into one all the time. Nothing here shows that an oral BPC-157 product delivers a meaningful quantity to the bloodstream. Nothing here shows that it delivers none. What can be said is that the compound is marketed on a gastric name, that the only route with a measured bioavailability is a needle, and that the single published route comparison ran the other way [5]. A reader who wants the honest summary can have it in one line. The oral question for BPC-157 has not been asked properly yet, and a capsule is not an answer to it. --- An independent reading desk on what survives the trip from mouth to bloodstream, selling nothing, prescribing nothing and endorsing no capsule, spray or protocol.